Tesamorelin 10MG

Tesamorelin is a synthetic peptide analogue of the growth hormone-releasing hormone (GHRH) with selective binding affinity for growth hormone-releasing hormone receptors (GHRHR). This product is intended exclusively for research applications within approved scientific, academic, or institutional settings.

Research Context

Tesamorelin has been investigated primarily as a tool to study the mechanisms of growth hormone (GH) signaling and its regulation, particularly in relation to obesity, diabetes, and metabolic disorders. Originally developed to explore GH’s role in the gastrointestinal tract, its selective activity in promoting lipolysis has prompted additional research into its potential therapeutic applications in conditions like lipodystrophy.

Research Overview

Tesamorelin is distinguished by its ability to selectively stimulate lipolysis (fat breakdown) while minimizing systemic effects on muscle tissue or overall growth hormone levels. Its research utility lies in enabling investigators to dissect the metabolic effects of GH signaling at a cellular and molecular level. Early studies have focused on its potential to reverse visceral fat accumulation in animal models, particularly in contexts where GH resistance is present.

Key Research Focus Areas

• Metabolic Regulation: Exploration of tesamorelin’s effects on lipid metabolism, including visceral fat reduction and improvement in lipid profiles, in models of obesity or metabolic syndrome.
• Growth Hormone Signaling: Investigation of tesamorelin’s mechanism of action compared to native GHRH, particularly its receptor binding specificity and downstream signaling pathways.
• Obesity Models: Assessment of tesamorelin’s efficacy in rodent and non-human primate models of lipodystrophy or diabetes-associated fat redistribution.
• Cellular and Molecular Biology: Examination of tesamorelin-induced gene expression changes in adipose tissue, such as upregulation of lipolytic enzymes (e.g., hormone-sensitive lipase) and downregulation of adipogenic markers.
• Comparative Pharmacology: Contrasting tesamorelin’s metabolic effects with those of other GH-related peptides, such as pegvisomant (a GHRH antagonist), to better understand GH resistance mechanisms.

Safety and Compliance

While tesamorelin has shown promising effects in controlled research settings, its safety profile in long-term or human applications remains undefined within the scope of this product. Users must adhere to strict research-use-only protocols, including proper storage conditions (e.g., refrigeration) and disposal procedures to prevent accidental exposure. This product is not intended for clinical testing, therapeutic use, or any non-academic applications.

For research use only. Not for human or animal consumption.